Multicenter study on the Pharmacokinetics and pharmacogenetics of crizotinib in patients with ALK fusion gene positive NSCLC

Trial Profile

Multicenter study on the Pharmacokinetics and pharmacogenetics of crizotinib in patients with ALK fusion gene positive NSCLC

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 May 2016

At a glance

  • Drugs Crizotinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Pharmacogenomic; Pharmacokinetics
  • Most Recent Events

    • 09 Sep 2015 Results presented at the 16th World Conference on Lung Cancer.
    • 09 Sep 2015 Status changed from active, no longer recruiting to completed, as reported at the 16th World Conference on Lung Cancer.
    • 12 Feb 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top